Data from IL18 Receptor Signaling Regulates Tumor-Reactive CD8<sup>+</sup> T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model

DOI: 10.1158/2326-6066.c.6534760.v1 Publication Date: 2023-04-03T13:45:59Z
ABSTRACT
&lt;div&gt;Abstract&lt;p&gt;Intratumoral cytotoxic CD8&lt;sup&gt;+&lt;/sup&gt; T cells (CTL) enter a dysfunctional state characterized by expression of coinhibitory receptors, loss effector function, and changes in the transcriptional landscape. Even though several regulators T-cell exhaustion have been identified, molecular mechanisms inducing remain unclear. Here, we show that IL18 receptor (IL18R) signaling induces murine pancreatic cancer model. Adoptive transfer &lt;i&gt;Il18r&lt;sup&gt;−/−&lt;/sup&gt;&lt;/i&gt; OT-1 CTLs resulted enhanced rejection subcutaneous tumors expressing ovalbumin (OVA) as model antigen (Panc&lt;sup&gt;OVA&lt;/sup&gt;), compared with wild-type CTLs. Transferred intratumoral IL18R-deficient expressed higher levels cytokines TNF IFNγ had reduced receptors (PD-1, TIM-3, 2B4, LAG-3) transcription factors Eomes TOX. Lower TOX on versus IL18R-sufficient were confirmed an orthotopic KPC IL18R-induced was regulated IL2/STAT5 AKT/mTOR pathways, demonstrated &lt;i&gt;in vitro&lt;/i&gt; assay. Concordantly, mice deficient NLRP3, complex activating IL18, decreased similar pathways at transcriptome level. Thus, promoting indicate involvement NLRP3-expressing tumor microenvironment, which mediates release. The Cancer Genome Atlas analysis patients carcinoma showed association between NLRP3-mediated shorter survival. These findings IL18R regulator possible target for immunotherapy.&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;a href="https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-23-0145" target="_blank"&gt;See related Spotlight Stromnes, p. 400&lt;/a&gt;&lt;/i&gt;&lt;/p&gt;&lt;/div&gt;
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)